Comparing the immunogenicity and safety of 3 Japanese encephalitis vaccines in Asia-Pacific area: A systematic review and meta-analysis.
Japanese encephalitis virus (JEV), a leading cause of Japanese encephalitis (JE) in children and adults, is a major public health problem in Asian countries. This study reports a meta-analysis of the immunogenicity and safety of vaccines used to protect infants or children from JE. Three types of JE vaccine were examined, namely, Japanese encephalitis live-attenuated vaccine (JEV-L), Japanese encephalitis inactivated vaccine (Vero cell) (JEV-I(Vero)), and Japanese encephalitis inactivated vaccine (primary hamster kidney cell) (JEV-I(PHK)). These vaccines are used to induce fundamental immunity against JE; however, few studies have compared their immunogenicity and safety in infants and young children less than 2 years of age. Data were obtained by searching 5 databases: Web of Science, PubMed, China National Knowledge Infrastructure, the China Wanfang database, and the Cochrane database. Fifteen articles were identified and scored using the Jadad score for inclusion in the meta-analysis. Random effect models were used to calculate the pooled seroconversion rate and adverse reaction rate when tests for heterogeneity were significant. The results showed that the pooled seroconversion rate for JEV-I(PHK) (62.23%) was lower than that for JEV-I(Vero) (86.49%) and JEV-L (83.52%), and that the pooled adverse reaction rate for JEV-L (18.09%) was higher than that for JEV-I(PHK) (10.08%) and JEV-I(Vero) (12.49%). The pooled relative risk was then calculated to compare the seroconversion and adverse reaction rates. The results showed that JEV-I(Vero) and JEV-L were more suitable than JEV-I(PHK) for inducing fundamental immunity to JE in infants and children less than 2 years of age.
a Department of Epidemiology and Biostatistics; School of Public Health; Southeast University ; Nanjing , Jiangsu , China.
Shi-Yuan
SY
Wang
Xiao-Hua
XH
Cheng
Jing-Xin
JX
Li
Xi-Yan
XY
Li
Feng-Cai
FC
Zhu
Pei
P
Liu
D000914:Antibodies, Viral / Q000097:blood; D001208:Asia / Q000453:epidemiology; D064420:Drug-Related Side Effects and Adverse Reactions / Q000453:epidemiology; D004672:Encephalitis, Japanese / Q000517:prevention & control*; D006801:Humans; D022321:Japanese Encephalitis Vaccines / Q000009:adverse effects* / Q000276:immunology*; D010139:Pacific Islands / Q000453:epidemiology; D014613:Vaccines, Attenuated / Q000008:administration & dosage / Q000276:immunology; D015164:Vaccines, Inactivated / Q000008:administration & dosage / Q000276:immunology
D000914:Antibodies, Viral; D022321:Japanese Encephalitis Vaccines; D014613:Vaccines, Attenuated; D015164:Vaccines, Inactivated
JE, Japanese encephalitis; JE-SV, JE subunit vaccine; JEV-I(PHK), Japanese encephalitis inactivated vaccine (Primary Hamster Kidney cell); JEV-I(Vero), Japanese encephalitis inactivated vaccine (Vero cell); JEV-I, Japanese encephalitis inactivated vaccine; JEV-L, Japanese encephalitis live-attenuated vaccine; JEV-PIV, Japanese encephalitis purified inactivated vaccine (Vero cell-derived SA14-14-2 strain); Japanese encephalitis vaccines; RCT, randomized controlled trial; RR, relative risk; adverse reaction rate; children; fundamental immunity; infants; meta-analysis; seroconversion rate